8 results about "Pyrimidine analogue" patented technology

A pharmaceutical composition including a nucleoside analogue loaded into liposomes of a liposomal delivery system, wherein the nucleoside analogue is a purine analogue chosen from {[2-(6-amino-9H-purin-9-yl)quinazolin-4-yl]oxy}phosphonic acid or 2-(6-amino-9H-purin-9-yl) quinazolin-4-ol, or a pyrimidine analogue chosen from 4-amino-1-(4-hydroxyquinazolin-2-yl)-1,2-dihydropyrimidin-2-one or N-[1-(4-hydroxyquinazolin-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl]acetamide.

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:wherein the variables are defined herein.

The invention discloses pyrimidine analogue and autophagy inhibitor co-loaded liposome and a preparation method of the pyrimidine analogue and autophagy inhibitor co-loaded liposome. The liposome is loaded with a pyrimidine analogue antitumor drug and an autophagy inhibitor, and the lipid of the liposome is composed of phospholipid and cholesterol; the weight ratio of the pyrimidine analogue antitumor drug to the autophagy inhibitor is 1: (1-10), and the weight ratio of the phospholipid to the cholesterol is (1-20): 1. The co-loaded liposome can efficiently load two drugs, the drug co-loading proportion can be controlled, drug release can be controlled, and the curative effect is remarkably improved. Compared with the prior art, the preparation method of the co-loaded liposome is easier to realize commercialized production, other solubilizing agent components are not added except phospholipid, the drug loading capacity of pyrimidine analogues can reach 5% or above, even 10% or above, and the preparation method is obviously superior to the prior art.

The present invention relates to a combination comprising: a therapeutically effective amount of a menin-mixed lineage leukemia 1 (menin-MLL) inhibitor; and a therapeutically effective amount of a DNA intercalator and a pyrimidine analogue; and to methods of treating a subject diagnosed with cancer using such combinations.

The present invention relates generally to the fields of cancer cell biology, cancer therapeutics for cancers located within in the central nervous system, thymidine analogs and cellular nucleotide excision repair mechanisms. More specifically, the invention relates to the use of EdU in methods of treating cancers located within in the central nervous system, and methods of inhibiting and / or reducing growth of a cancer or cancer cell.

Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing a viral infection:

Disclosed are combinations comprising a therapeutically effective amount of a multiple endocrine cancer protein-MLL inhibitor of formula (I), or a pharmaceutically acceptable salt or solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent, which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalator, a pyrimidine analogue, a purine analogue, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulator, or a DHODH inhibitor. Also disclosed are methods for treating a subject that has been diagnosed with cancer using such combinations. The compounds are represented by the following formula (I): # imgabs0 # wherein the variables are defined herein.